fibrosis

(redirected from Idiopathic pulmonary fibrosis)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

fi·bro·sis

 (fī-brō′sĭs)
n.
The formation of excessive fibrous tissue, as in a reparative or reactive process.

fi·brot′ic (-brŏt′ĭk) adj.

fibrosis

(faɪˈbrəʊsɪs)
n
(Pathology) the formation of an abnormal amount of fibrous tissue in an organ or part as the result of inflammation, irritation, or healing
fibrotic adj

fi•bro•sis

(faɪˈbroʊ sɪs)

n.
the development in an organ of excess fibrous connective tissue.
[1870–75]
fi•brot′ic (-ˈbrɒt ɪk) adj.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.fibrosis - development of excess fibrous connective tissue in an organ
pneumoconiosis, pneumonoconiosis - chronic respiratory disease caused by inhaling metallic or mineral particles
cystic fibrosis, fibrocystic disease of the pancreas, mucoviscidosis, pancreatic fibrosis, CF - the most common congenital disease; the child's lungs and intestines and pancreas become clogged with thick mucus; caused by defect in a single gene; no cure is known
pathology - any deviation from a healthy or normal condition
myelofibrosis - fibrosis of the bone marrow
Translations

fibrosis

[faɪˈbrəʊsɪs] nfibrosi f

fi·bro·sis

n. fibrosis, formación anormal de tejido fibroso;
diffuse interstitial pulmonary ______ intersticial del pulmón;
proliferative ______ proliferativa;
retroperineal ______ retroperineal.

fibrosis

n fibrosis f; idiopathic pulmonary — fibrosis pulmonar idiopática; nephrogenic systemic — fibrosis sistémica nefrogénica
References in periodicals archive ?
Azathioprine, penicillamine, chlorambucill vincristine sulfate, and colchicine have been used in a few patients with idiopathic pulmonary fibrosis.
s (TSX: PLI; OTCQX: PFSCF) orally-active drug candidate, PBI-4050, has been issued a Promising Innovative Medicine (PIM) designation by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) as add-on treatment to nintedanib in patients with idiopathic pulmonary fibrosis, the company said.
The report reviews key players involved in the therapeutics development for Idiopathic Pulmonary Fibrosis and enlists all their major and minor projects
With the strong strategic fit between our companies, we intend to continue to move PRM-151 forward rapidly as a new treatment option to address the unmet needs of patients with myelofibrosis, idiopathic pulmonary fibrosis, and other fibrotic diseases.
Bristol-Myers Squibb is developing an early stage fibrosis portfolio that includes BMS-986020, a lysophosphatidic acid 1 receptor antagonist in Phase 2 development for the treatment of idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults.
Idiopathic pulmonary fibrosis was defined in the 2000 international consensus statement (4) on its diagnosis and treatment as a specific form of chronic fibrosing interstitial pneumonia limited to the lung and associated with the histologic appearance of usual interstitial pneumonia (UIP) on surgical (thoracoscopic or open) lung biopsy.
The FDA's Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of pirfenidone for reduction in the decline of lung function in idiopathic pulmonary fibrosis (IPF).
InterMune agreed in October to pay $37 million to settle charges it promoted Actimmune to treat idiopathic pulmonary fibrosis, a condition involving scarring of lung tissue.
Neither ACE inhibitors nor statins appear to improve survival in patients with idiopathic pulmonary fibrosis, reported Hassan F.

Full browser ?